Skip to main content Skip to search Skip to main navigation

EMA: Comments on the current ICH guideline Q9 (R1) quality risk management

The EMA has released the comments of the ICH guideline Q9 (R1) draft from december 2021 in late april. The document contributes principles and examples of tools for quality risk management. The document consists of 56 pages of comments from organizations such as the PDA, EFPIA and many others. In the following some excerpts:

General comments of the ISPE

The ISPE wrote several comments with recommendet changes, e.g. the general comment on page 2, in which the ISPE suggests that the basis of QRM activities is to be aware of the underlying risk, regardless of the formal level at which the risk exists. The ICH guideline states that the level of effort, formality and documentation of the QRM process should be commensurate with the risk.

Regarding the newly included concept of formality in QRM, the ISPE stated: „One of the stated objectives of ICH Q9 R1 is to expand on the concept of "formality" in Quality Risk Management. The Principles of Quality Risk Management (section 3) correctly states that "the level of effort, formality and documentation of the QRM process should be commensurate with the level of risk". Formality in Quality Risk Management (section 5.1) also correctly states that QRM is not binary (formal vs informal) but rather a continuum ranging from low to high. However, when the characteristics of risk assessments are described in lines 281 to 300, the impression of a binary system is given. High levels of formality are described as having a cross-functional team, use various QRM tools with all steps of the QRM process explicitly performed. By contrast the characteristics of lower formality are implied to always be imbedded and documented in other elements of the Quality System. ISPE considers that all Quality Risk Management exercises begin with the most informal of activities; that of asking a question. Questions are described in section 4.3 Risk Assessment […].

Their proposed change is „ISPE believes that asking the initial fundamental 'risk question' is the foundation of all QRM activities, regardless of what level of formality is ultimately used. It is also believed that, depending on the initial answers, the process may end there with minimal or no documentatio […].

Furthermore, the ISPE wrote "The section on formality gives the impression that informal risk assessments are always covered by a QMS/PQS procedure. This is not always the case e.g. equipment selection against CPP's/CAs, preliminary risk management exercise applied in the early phases of risk assessment when comparing proposed process steps using, for example preliminary hazard analysis tool."

They suggest that the principle of a proactive risk culture should be developed, recommending included guidance on a continuum from informal to formal risk assessment, which does not always have to be linked to a PQS element.

 

ECA Foundation and it's expert group, the European QP Assosiation (EQPA)

On page 23 the Foundation and its expert group published, among others, a comment on section 5.2, line 303 ff: "Effective risk-based decision making begins with determining the level of effort, formality and documentation that should be applied during the quality risk management process. The statement is not correct. "Effective risk-based decision making" is the result (the consequence) of the risk management effort."

They reason that effective risk-based decision making begins with determining the level of effort, formality and documentation that should be applied during the quality risk management process.

 

In the third step of the revision of ICH Guideline Q9, the comments are now being reviewed and further processed by ICH.


Source:

EMA: ICH Q9 Quality risk management

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
What are the General Requirements for Standard Documents?

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
EDQM: Revised Guidance on Sister File Applications

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
Previous
Next